Lazard Asset Management LLC Sells 108,947 Shares of Royalty Pharma PLC $RPRX

Posted by Brian Himes on Aug 5th, 2026

Lazard Asset Management LLC decreased its stake in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 81.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,163 shares of the biopharmaceutical company’s stock after selling 108,947 shares during the quarter. Lazard Asset Management LLC’s holdings in Royalty Pharma were worth $1,159,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Morgan Stanley raised its stake in Royalty Pharma by 25.2% during the fourth quarter. Morgan Stanley now owns 55,274,069 shares of the biopharmaceutical company’s stock worth $2,135,790,000 after acquiring an additional 11,110,115 shares in the last quarter. Capital International Investors boosted its stake in shares of Royalty Pharma by 14.3% in the 4th quarter. Capital International Investors now owns 31,104,309 shares of the biopharmaceutical company’s stock valued at $1,201,870,000 after purchasing an additional 3,891,615 shares in the last quarter. State Street Corp boosted its stake in shares of Royalty Pharma by 3.7% in the 4th quarter. State Street Corp now owns 10,649,641 shares of the biopharmaceutical company’s stock valued at $411,502,000 after purchasing an additional 376,888 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Royalty Pharma by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 7,719,843 shares of the biopharmaceutical company’s stock worth $297,465,000 after purchasing an additional 102,430 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in shares of Royalty Pharma by 9.7% in the 4th quarter. Victory Capital Management Inc. now owns 5,106,905 shares of the biopharmaceutical company’s stock worth $197,331,000 after purchasing an additional 449,498 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on RPRX. TD Cowen increased their target price on shares of Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Citigroup upped their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings lowered shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. UBS Group raised their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Finally, Morgan Stanley lifted their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research note on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $56.57.

Read Our Latest Analysis on RPRX

Insider Activity at Royalty Pharma

In related news, EVP Marshall Urist sold 13,684 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $52.75, for a total value of $721,831.00. Following the completion of the transaction, the executive vice president owned 18,197 shares in the company, valued at $959,891.75. The trade was a 42.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 150,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $54.40, for a total value of $8,160,000.00. Following the transaction, the executive vice president directly owned 559,399 shares in the company, valued at approximately $30,431,305.60. This represents a 21.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 393,009 shares of company stock valued at $21,601,827 over the last ninety days. Company insiders own 18.84% of the company’s stock.

Royalty Pharma Price Performance

Shares of RPRX stock opened at $57.48 on Wednesday. Royalty Pharma PLC has a 52 week low of $34.08 and a 52 week high of $60.44. The stock has a market capitalization of $33.10 billion, a PE ratio of 39.10, a PEG ratio of 10.13 and a beta of 0.43. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The stock’s fifty day moving average is $56.32 and its 200-day moving average is $50.17.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $630.58 million during the quarter, compared to analysts’ expectations of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. Equities research analysts expect that Royalty Pharma PLC will post 5.18 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.6%. Royalty Pharma’s payout ratio is currently 63.95%.

Royalty Pharma Profile

(Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.